The PedsQL Family Impact Module: preliminary reliability and validity.
James W Varni, Sandra A Sherman, Tasha M Burwinkle...
https://pubmed.ncbi.nlm.nih.gov/15450120/Actively Recruiting
Led by Nader Shaikh · Updated on 2026-10-20
1100
Participants Needed
5
Research Sites
12 weeks
Total Duration
Researchers are studying the effectiveness of antibiotics in children aged 2 to under 12 years with acute sinusitis, a common sinus infection. The study aims to understand whether antibiotics like amoxicillin or amoxicillin-clavulanate help reduce symptom severity compared with a placebo. It also examines how factors such as allergy symptoms or illness severity might influence treatment outcomes to guide better decisions in treating pediatric sinus infections. Participants are randomly assigned to one of four groups receiving either amoxicillin, amoxicillin-clavulanate, or matching placebos for these antibiotics. The treatments are given orally based on weight-appropriate doses following pediatric guidelines. Caregivers complete daily electronic symptom diaries during the treatment period to report the childs symptoms. The study is double-blind, so neither families nor staff know which treatment the child receives. During the study, caregivers report symptoms daily for 10 days using an electronic diary to track symptom severity. Researchers also monitor safety outcomes like diarrhea during this period and observe for recurrence of sinusitis or ear infections for up to 90 days. The studys main measurement is the average daily symptom burden over the first 10 days. The trial runs from October 2026 through March 2032, with regular data collection and follow-up to assess treatment effects and safety.
CONDITIONS
Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Sinusitis)
J
Jane Luce, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Nader Shaikh
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Amoxicillin | Amoxicillin-Clavulanate | Amoxicillin Placebo | Amoxicillin-Clavulanate Placebo |
|---|---|---|---|---|
| What is it? | Oral antibiotic in the penicillin class, commonly used for pediatric bacterial infections including acute sinusitis. | Oral combination antibiotic including amoxicillin plus clavulanate, which extends antimicrobial spectrum and targets beta-lactamase–producing bacteria. | A matching placebo that appears identical to amoxicillin, containing no active antibiotic agent; used for blinding and control. | A matching placebo identical to amoxicillin-clavulanate but without any active antibiotics; used to blind and control the active arm. |
| Role in the trial | Investigational treatment arm to determine the effectiveness of amoxicillin for acute sinusitis in children. | Investigational comparator arm to assess if adding clavulanate to amoxicillin offers additional benefit. | Control arm to assess outcomes in children not receiving active amoxicillin; enables blinded comparison. | Control arm to assess outcomes in children not receiving amoxicillin-clavulanate; enables blinded comparison to the active comparator. |
| Primary use | First-line oral antibiotic for acute bacterial sinusitis in otherwise healthy children. | First-line oral antibiotic preferred when beta-lactamase–producing pathogens are likely or risk factors are present. | Used only as an inactive control in clinical trials, not a treatment for sinusitis. | Used only as an inactive control in clinical trials, not a treatment for sinusitis. |
| How is it given or performed? | Given by mouth in weight-based doses for the defined treatment duration, following standard pediatric protocols. | Given by mouth in weight-based doses for the defined treatment duration, per pediatric protocol recommendations. | Oral placebo identical in appearance to amoxicillin but with no active antibiotic. | Oral placebo identical in appearance to amoxicillin-clavulanate but containing no active ingredients. |
| Evidence status | Amoxicillin is supported by pediatric guidelines and prior trials as effective initial therapy for most children with acute bacterial sinusitis. However, some children benefit less, and this ongoing trial seeks to clarify which subgroups improve the most. | Amoxicillin-clavulanate is guideline-endorsed for specific risk groups or high local resistance, but increasing use is balanced against potential side effects. This trial examines added benefit over amoxicillin alone. | Inactive; used to measure the real effect of antibiotics over natural recovery. External evidence shows most uncomplicated cases resolve, but some benefit from targeted antibiotics. | Inactive; allows for blinded control of the amoxicillin-clavulanate group. Used to assess the effect of the antibiotic in excess of placebo response. |
| Important limitations | Not all children with acute sinusitis require antibiotics. Overuse can contribute to antibiotic resistance and risk for side effects such as rash or diarrhea. | Can be associated with higher rates of gastrointestinal side effects, including diarrhea, compared to amoxicillin alone. Risk of antibiotic resistance remains. | No antibacterial effect; some children could experience slower recovery or complications without targeted antibiotic therapy. | No antibacterial effect; similar risks apply as for the amoxicillin placebo group regarding illness duration or potential for complications. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - 10 days
Participants receive oral amoxicillin, amoxicillin-clavulanate, or a matching placebo for acute sinusitis. Caregivers complete daily electronic symptom diaries during this period.
Daily symptom diary entries
Duration - 80 days
Researchers monitor for safety outcomes such as diarrhea and check for recurrence of sinusitis or ear infections over the next 80 days after treatment.
Periodic follow-up assessments
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
James W Varni, Sandra A Sherman, Tasha M Burwinkle...
https://pubmed.ncbi.nlm.nih.gov/15450120/James W Varni, Tasha M Burwinkle, Michael Seid...
https://pubmed.ncbi.nlm.nih.gov/14616041/Nader Shaikh, Alejandro Hoberman, Timothy R Shope...
https://pubmed.ncbi.nlm.nih.gov/37490085/James W Varni, Christine A Limbers, Katie Neighbors...
https://pubmed.ncbi.nlm.nih.gov/20730626/Nader Shaikh, Ellen R Wald, Jong-Hyeon Jeong...
https://pubmed.ncbi.nlm.nih.gov/30545562/Ellen R Wald, Kimberly E Applegate, Clay Bordley...
https://pubmed.ncbi.nlm.nih.gov/23796742/Nader Shaikh
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor